BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ding ZM, Xiao Y, Wu X, Zou H, Yang S, Shen Y, Xu J, Workman HC, Usborne AL, Hua H. Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy. Front Pharmacol. 2018;9:410. [PMID: 29765319 DOI: 10.3389/fphar.2018.00410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, Gracia-Sancho J. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021;15:36-50. [PMID: 33544313 DOI: 10.1007/s12072-021-10135-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Hansen HH, Ægidius HM, Oró D, Evers SS, Heebøll S, Eriksen PL, Thomsen KL, Bengtsson A, Veidal SS, Feigh M, Suppli MP, Knop FK, Grønbæk H, Miranda D, Trevaskis JL, Vrang N, Jelsing J, Rigbolt KTG. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol 2020;20:210. [PMID: 32631250 DOI: 10.1186/s12876-020-01356-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
3 Baandrup Kristiansen MN, Veidal SS, Christoffersen C, Feigh M, Vrang N, Roth JD, Erickson M, Adorini L, Jelsing J. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. BMC Gastroenterol 2019;19:228. [PMID: 31883514 DOI: 10.1186/s12876-019-1149-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Boland ML, Oró D, Tølbøl KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE, Fernandes F, Tovchigrechko A, Veidal SS, Warrener P, Sellman BR, Jelsing J, Feigh M, Vrang N, Trevaskis JL, Hansen HH. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J Gastroenterol 2019; 25(33): 4904-4920 [PMID: 31543682 DOI: 10.3748/wjg.v25.i33.4904] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 33] [Article Influence: 13.7] [Reference Citation Analysis]
5 Wang X, Fu T, Wang J, Wang C, Liu K, Wu J, Sun H, Ma X, Sun P, Meng Q. Hepatoprotection of yangonin against hepatic fibrosis in mice via farnesoid X receptor activation. Int Immunopharmacol 2019;75:105833. [PMID: 31450152 DOI: 10.1016/j.intimp.2019.105833] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Patel DP, Yan T, Kim D, Dias HB, Krausz KW, Kimura S, Gonzalez FJ. Withaferin A Improves Nonalcoholic Steatohepatitis in Mice. J Pharmacol Exp Ther 2019;371:360-74. [PMID: 31420528 DOI: 10.1124/jpet.119.256792] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
7 Roth JD, Veidal SS, Fensholdt LKD, Rigbolt KTG, Papazyan R, Nielsen JC, Feigh M, Vrang N, Young M, Jelsing J, Adorini L, Hansen HH. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. Sci Rep 2019;9:9046. [PMID: 31227742 DOI: 10.1038/s41598-019-45178-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
8 Dang Y, Hao S, Zhou W, Zhang L, Ji G. The traditional Chinese formulae Ling-gui-zhu-gan decoction alleviated non-alcoholic fatty liver disease via inhibiting PPP1R3C mediated molecules. BMC Complement Altern Med 2019;19:8. [PMID: 30616587 DOI: 10.1186/s12906-018-2424-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]